Kyverna Therapeutics, Inc.

NASDAQ:KYTX

Biotechnology

Healthcare
$4.48 -1.44%

-$0.12 today

Market cap
$283.23M
Beta
1.96
P/E (TTM)
-3.1
EPS (TTM)
-$2.59
52W Low $2.52High $13.67

Volume 1.05M

Average 0.94M

KYTX Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Kyverna Therapeutics, Inc.NASDAQ: KYTX

Operating Margin · Q1 FY2026 · quarter ended Mar 2026

Operating margin not reported for Q1 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
—— YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2022
-418.3%
Year-over-year change
+47.5pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How KYTX compares with its peers on the latest reported figures

KYTX Competitors Peer median
Operating Margin for KYTX and competitors
Company Period LTM level YoY 3-year change
EDITEditas Medicine, Inc.LTM Mar 2026-297.5% +428.9 pp+901.1 pp
MREOMereo BioPharma Group plcLTM Mar 2026-7531.1% ——
SLNSilence Therapeutics plcLTM Mar 2026-9396.6% —-15774.1 pp
LYELLyell Immunopharma, Inc.LTM Mar 2026-618909.7% -64222.0 pp-565818.0 pp
KYTXKyverna Therapeutics, Inc.FY2025— ——
CAPRCapricor Therapeutics, Inc.FY2025— ——
CTNMContineum Therapeutics, Inc. Class A Common StockFY2025— ——
AVIRAtea Pharmaceuticals, Inc.FY2025— ——
ALLOAllogene Therapeutics, Inc.FY2025— ——
CABACabaletta Bio, Inc.FY2025— ——
LXEOLexeo Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding KYTX) -8463.9%-31896.5 pp-15774.1 pp

Competitors are the stored peer set for KYTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.66M7.03M000
Cost of Revenue001.71M2.13M0
Gross Profit5.66M7.03M(1.71M)(2.13M)0
Gross Margin100.0%100.0%———
Research & Development25.85M28.4M48.22M112.47M133.72M
Selling, General & Admin6.15M8.01M12.48M30.13M36.11M
Operating Expenses32M36.41M60.7M140.47M169.83M
Depreciation & Amortization586K1.05M1.71M2.13M1.8M
EBITDA(25.76M)(27.78M)(58.47M)(125.2M)(159.02M)
EBITDA Margin-455.5%-395.4%———
Operating Income(26.35M)(29.38M)(62.41M)(142.6M)(169.83M)
Operating Margin-465.8%-418.3%———
Interest Income1K565K2.28M15.36M9.09M
Interest Expense3K65K187K142K489K
Other Income / Expenses(4K)491K2.04M15.13M8.52M
Income Before Tax(26.35M)(28.89M)(60.37M)(127.48M)(161.31M)
Pre-Tax Margin-465.9%-411.3%———
Income Tax Expense00000
Net Income(26.35M)(28.89M)(60.37M)(127.48M)(161.31M)
Net Margin-465.9%-411.3%———
EPS (Basic)(1.02)(1.12)(0.00)(3.33)(3.64)
EPS (Diluted)(1.02)(1.12)(0.00)(3.33)(3.64)
Weighted Avg Shares25.8M25.8M673.62M38.33M44.26M
Weighted Avg Shares (Diluted)25.8M25.8M673.62M38.33M44.26M

Kyverna Therapeutics, Inc.

NASDAQ:KYTX

Intrinsic Alpha fair value

Locked

Current Price

$4.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.